Literature DB >> 22994556

Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.

J A McCombe1, P Vivithanaporn, M J Gill, C Power.   

Abstract

OBJECTIVES: The aim of the study was to determine the risk factors predictive of symptomatic HIV-associated neurocognitive disorders (sHAND) among HIV-infected patients receiving active medical care.
METHODS: Baseline demographic and clinical characteristics were analysed in patients with sHAND (HIV-associated dementia and minor neurocognitive disorder) in a population-based longitudinal cohort of HIV-infected patients with access to universal health care, including combination antiretroviral therapy (cART) from 1999 to 2008. Variables evaluated for their association with sHAND included age and ethnicity, survival duration with HIV-1 infection, vascular disease risk factors, and laboratory indices such as blood CD4 T-cell count at its nadir and at cART initiation, using both univariable and multivariable logistic regression models.
RESULTS: A total of 1320 patients were investigated, including the patients diagnosed with sHAND (n = 90) during the study period. In univariable analyses, increased age, increased length of survival with HIV, low nadir CD4 and CD8 T-cell counts, high baseline viral load (> 1,000,000 HIV-1 RNA copies/mL), and African origin were predictive of a diagnosis of sHAND (P < 0.05). In multivariable analysis, increased age, increased length of survival, low nadir CD4 T-cell counts, and high baseline viral load remained predictive of sHAND (P < 0.05). Remarkably, CD4 T-cell counts at cART initiation, hepatitis C virus coinfection, and vascular disease risk factors failed to predict sHAND in both analyses.
CONCLUSIONS: Increased age and survival duration, lower nadir CD4 T-cell counts, and higher baseline viral load were consistent predictors of the development of sHAND among persons with HIV/AIDS in universal health care, underscoring the importance of attention to these variables in clinical care.
© 2012 British HIV Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22994556     DOI: 10.1111/j.1468-1293.2012.01043.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  29 in total

1.  Empiric neurocognitive performance profile discovery and interpretation in HIV infection.

Authors:  Daniela Gomez; Christopher Power; M John Gill; Noshin Koenig; Roberto Vega; Esther Fujiwara
Journal:  J Neurovirol       Date:  2018-12-05       Impact factor: 2.643

2.  HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction.

Authors:  Eugene L Asahchop; William G Branton; Anand Krishnan; Patricia A Chen; Dong Yang; Linglong Kong; Douglas W Zochodne; Bruce J Brew; M John Gill; Christopher Power
Journal:  JCI Insight       Date:  2018-12-06

Review 3.  Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment.

Authors:  Jay Rappaport; David J Volsky
Journal:  J Neurovirol       Date:  2015-05-02       Impact factor: 2.643

4.  A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review.

Authors:  Mark Bloch; Jody Kamminga; Avindra Jayewardene; Michael Bailey; Angela Carberry; Trina Vincent; Dick Quan; Paul Maruff; Bruce Brew; Lucette A Cysique
Journal:  Clin Infect Dis       Date:  2016-06-19       Impact factor: 9.079

5.  Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients.

Authors:  Massimiliano Fabbiani; Nicoletta Ciccarelli; Valeria Castelli; Alessandro Soria; Alberto Borghetti; Elisa Colella; Davide Moschese; Manuela Valsecchi; Arianna Emiliozzi; Andrea Gori; Andrea De Luca; Alessandra Bandera; Simona Di Giambenedetto
Journal:  J Neurovirol       Date:  2019-07-07       Impact factor: 2.643

6.  HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project.

Authors:  N S Ku; Y Lee; J Y Ahn; J E Song; M H Kim; S B Kim; S J Jeong; K-W Hong; E Kim; S H Han; J Y Song; H J Cheong; Y G Song; W J Kim; J M Kim; D M Smith; J Y Choi
Journal:  HIV Med       Date:  2014-02-24       Impact factor: 3.180

7.  Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders.

Authors:  Anjana Yadav; Michael R Betts; Ronald G Collman
Journal:  J Neurovirol       Date:  2016-03-28       Impact factor: 2.643

8.  Spatiotemporal dynamics of simian immunodeficiency virus brain infection in CD8+ lymphocyte-depleted rhesus macaques with neuroAIDS.

Authors:  Samantha L Strickland; Brittany D Rife; Susanna L Lamers; David J Nolan; Nazle M C Veras; Mattia C F Prosperi; Tricia H Burdo; Patrick Autissier; Brian Nowlin; Maureen M Goodenow; Marc A Suchard; Kenneth C Williams; Marco Salemi
Journal:  J Gen Virol       Date:  2014-09-09       Impact factor: 3.891

9.  Association of age and time of disease with HIV-associated neurocognitive disorders: a Japanese nationwide multicenter study.

Authors:  Ei Kinai; Kensuke Komatsu; Maiko Sakamoto; Toshibumi Taniguchi; Aya Nakao; Hidetoshi Igari; Kiyonori Takada; Aki Watanabe; Ai Takahashi-Nakazato; Misao Takano; Yoshimi Kikuchi; Shinichi Oka
Journal:  J Neurovirol       Date:  2017-10-02       Impact factor: 2.643

10.  Machine learning models reveal neurocognitive impairment type and prevalence are associated with distinct variables in HIV/AIDS.

Authors:  Wei Tu; Patricia A Chen; Noshin Koenig; Daniela Gomez; Esther Fujiwara; M John Gill; Linglong Kong; Christopher Power
Journal:  J Neurovirol       Date:  2019-09-13       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.